Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK3134 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | MK3134-Lorazepam-Placebo-MK3134-Lorazepam |
| Sequence 2 | EXPERIMENTAL | MK3134-Lorazepam-Placebo-Lorazepam-MK3134 |
| Sequence 3 | EXPERIMENTAL | MK3134-Placebo-Lorazepam-MK3134-Lorazepam |
| Sequence 4 | EXPERIMENTAL | MK3134-Placebo-Lorazepam-Lorazepam-MK3134 |
| Sequence 5 | EXPERIMENTAL | Lorazepam-Placebo-MK3134-MK3134-Lorazepam |
| Sequence 6 | EXPERIMENTAL | Lorazepam-Placebo-MK3134-Lorazepam-MK3134 |
| Sequence 7 | EXPERIMENTAL | Lorazepam-MK3134-Placebo-MK3134-Lorazepam |
| Sequence 8 | EXPERIMENTAL | Lorazepam-MK3134-Placebo-Lorazepam-MK3134 |
| Sequence 9 | EXPERIMENTAL | Placebo-MK3134-Lorazepam-MK3134-Lorazepam |
| Sequence 10 | EXPERIMENTAL | Placebo-MK3134-Lorazepam-Lorazepam-MK3134 |
| Sequence 11 | EXPERIMENTAL | Placebo-Lorazepam-MK3134-MK3134-Lorazepam |
| Sequence 12 | EXPERIMENTAL | Placebo-Lorazepam-MK3134-Lorazepam-MK3134 |
| Part I | EXPERIMENTAL | Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences. |
| Part II | EXPERIMENTAL | Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences. |
| Name | Type | Description |
|---|---|---|
| MK3134 | DRUG | MK3134, 25 mg tablets (5 x 5 mg capsule), orally |
| Comparator: Lorazepam | DRUG | Lorazepam, 2 mg (2 x 1 mg tablet), orally |
| Comparator: Placebo | DRUG | Placebo, to match MK3134, and placebo to match Lorazepam |
| Donepezil | DRUG | Single dose 5 mg donepezil capsules in two of the four treatment periods. |
Inclusion Criteria: * Subject is a male between 18 to 40 years of age * The subject has a Body Mass Index (BMI) greater than or equal to 31 kg/m\^2 at the prestudy (screening) visit * Subject has normal or corrected to normal visual and auditory acuity * Subject has been a nonsmoker and/or has not ...
MK3134 is an investigational small molecule being developed by Merck & Company, Inc. for the treatment of dementia. It is currently in Phase 1 clinical development, meaning it is still being studied and has not been approved for use. The drug is being evaluated in early-stage trials to assess its safety and potential effects.
MK3134 is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is currently in Phase 1 clinical trials for dementia, and Merck is conducting research to evaluate its potential as a treatment for this condition.
MK3134 is in Phase 1 clinical development. It is an investigational drug being studied for dementia, and it has not yet been approved by regulatory authorities. The Phase 1 trials are designed to evaluate the drug's safety, tolerability, and early signals of activity in healthy volunteers.
MK3134 has been studied in two completed Phase 1 clinical trials. The first, NCT00887601, involved 32 healthy male participants and used BOLD functional magnetic resonance imaging to assess biomarkers for cognition-enhancing drugs. The second, NCT01110616, enrolled 25 healthy male subjects and focused on standardizing electroencephalogram platforms. Both trials were completed.
MK3134 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for dementia. The drug has completed two early-stage trials, but it has not yet demonstrated sufficient evidence of safety and efficacy to receive approval from the U.S. Food and Drug Administration or any other regulatory agency.